CN113874378A - 用于制备btk抑制剂的方法和中间体 - Google Patents

用于制备btk抑制剂的方法和中间体 Download PDF

Info

Publication number
CN113874378A
CN113874378A CN202080037397.5A CN202080037397A CN113874378A CN 113874378 A CN113874378 A CN 113874378A CN 202080037397 A CN202080037397 A CN 202080037397A CN 113874378 A CN113874378 A CN 113874378A
Authority
CN
China
Prior art keywords
compound
formula
ibrutinib
group
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080037397.5A
Other languages
English (en)
Chinese (zh)
Inventor
P·J·派伊
A·霍瓦特
C·Y·陈
Y·袁
J·苏
S·王
S·A·瓦格斯沙尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN113874378A publication Critical patent/CN113874378A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202080037397.5A 2019-05-21 2020-05-20 用于制备btk抑制剂的方法和中间体 Pending CN113874378A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019087823 2019-05-21
CNPCT/CN2019/087823 2019-05-21
PCT/EP2020/064123 WO2020234381A1 (en) 2019-05-21 2020-05-20 Processes and intermediates for preparing a btk inhibitor

Publications (1)

Publication Number Publication Date
CN113874378A true CN113874378A (zh) 2021-12-31

Family

ID=70857160

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080037397.5A Pending CN113874378A (zh) 2019-05-21 2020-05-20 用于制备btk抑制剂的方法和中间体

Country Status (11)

Country Link
US (1) US12215110B2 (https=)
EP (1) EP3972977A1 (https=)
JP (1) JP7658916B2 (https=)
KR (1) KR20220011668A (https=)
CN (1) CN113874378A (https=)
AU (1) AU2020278162A1 (https=)
BR (1) BR112021022347A2 (https=)
CA (1) CA3135240A1 (https=)
IL (1) IL288154A (https=)
MX (1) MX2021014246A (https=)
WO (1) WO2020234381A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12450495B2 (en) 2022-06-13 2025-10-21 International Business Machines Corporation Neural capacitance: neural network selection via edge dynamics

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101610676A (zh) * 2006-09-22 2009-12-23 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US20140275126A1 (en) * 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
CN105026400A (zh) * 2013-03-15 2015-11-04 詹森药业有限公司 用于制备药物的方法和中间体
CN107108640A (zh) * 2015-01-14 2017-08-29 药品循环有限责任公司 布鲁顿酪氨酸激酶抑制剂的合成

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2414363E (pt) * 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
SI3057969T1 (sl) 2013-10-17 2018-10-30 Blueprint Medicines Corporation Sestavki, uporabni za zdravljenje motenj, povezanih s KIT
JP6681922B2 (ja) 2015-02-12 2020-04-15 上▲海▼度▲徳▼医▲藥▼科技有限公司 イブルチニブの製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101610676A (zh) * 2006-09-22 2009-12-23 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US20140275126A1 (en) * 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
CN105026400A (zh) * 2013-03-15 2015-11-04 詹森药业有限公司 用于制备药物的方法和中间体
CN107108640A (zh) * 2015-01-14 2017-08-29 药品循环有限责任公司 布鲁顿酪氨酸激酶抑制剂的合成

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHENG-YI CHEN等: "A Copper-Catalyzed Tandem C–H ortho-Hydroxylation and N–N Bond-Formation Transformation: Expedited Synthesis of 1-(ortho-Hydroxyaryl)-1H-indazoles", 《EUR. J. ORG. CHEM.》, 31 December 2017 (2017-12-31), pages 6604, XP055705491, DOI: 10.1002/ejoc.201701149 *
CHENG-YI CHEN等: "A Synthesis of 1H‑Indazoles via a Cu(OAc)2‑Catalyzed N−N Bond Formation", 《ORG. LETT.》, vol. 18, 18 March 2016 (2016-03-18), pages 1691 - 1693 *

Also Published As

Publication number Publication date
EP3972977A1 (en) 2022-03-30
KR20220011668A (ko) 2022-01-28
BR112021022347A2 (pt) 2022-01-04
AU2020278162A1 (en) 2021-11-18
IL288154A (en) 2022-01-01
BR112021022347A8 (pt) 2021-12-28
US20220204516A1 (en) 2022-06-30
JP7658916B2 (ja) 2025-04-08
JP2022533747A (ja) 2022-07-25
MX2021014246A (es) 2022-01-06
CA3135240A1 (en) 2020-11-26
WO2020234381A1 (en) 2020-11-26
US12215110B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
AU2013203283B2 (en) Processes for the preparation of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine
CN111763209B (zh) 一种芦可替尼的合成工艺
JP6147769B2 (ja) アミノスルホン化合物の調製のための不斉合成方法
CN104262344A (zh) 艾德拉尼的制备方法
CN100473654C (zh) S型4-取代羟基吡喃并吲哚哩啶化合物和其衍生物以及其制备方法
CN107176955B (zh) 一种巴瑞替尼的制备方法
JP2016510779A (ja) 薬剤を調製するための方法と中間体
CN106977415B (zh) 一种沙库必曲的中间体及其制备方法
CN109485638B (zh) 一种奥希替尼中间体的制备方法
EP3148968A1 (en) Processes for the preparation of -aminosulfone compounds
CN113874378A (zh) 用于制备btk抑制剂的方法和中间体
CN103402973B (zh) 化合物及其生产方法，以及用于生产磷酸奥司他韦的方法
CN112218853A (zh) 用于立体选择性制备手性2-[(杂)芳烷基硫基]嘧啶类的方法和可由其获得的产物
HK40060540A (en) Processes and intermediates for preparing a btk inhibitor
RU2818458C2 (ru) Способы и промежуточные соединения для получения ингибитора btk
CN103787921B (zh) 一种制备高光学纯度的反式1,2-环二胺的方法
WO2018061034A1 (en) Novel process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine
CN112174837A (zh) 一种合成(R)-4-甲氧基-α-甲基苯乙胺的方法
CN112279849A (zh) 一种n-二氟甲基氮杂吲哚类化合物及其合成方法
KR100566562B1 (ko) 수마트립탄의 제조방법
CN106715402A (zh) 用于生产光学活性的戊酸衍生物的方法
HK40035220A (en) Processes for the preparation of (s)-1-(3-ethoxy-4- methoxyphenyl)-2-methanesulfonylethylamine
HK40053467A (en) Processes for the preparation of (s)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine
JP2005194266A (ja) インドール類の合成方法および合成中間体
JP2005255659A (ja) 官能基化された中員環アミン類とその製法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060540

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination